Form D · Biotechnology

Alcresta Therapeutics, Inc.

Warren, NJ · CIK 0001673510

Offering snapshot reported Mar 3, 2020 · SEC filing

Reported sold
$10M
Offering amount: $20M
Investors reported
17
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 28, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 3, 2020Initial$10,000,004No comparison17SEC filing
Jan 23, 2019Initial$5,000,008No comparison19SEC filing
Sep 25, 2017Initial$9,999,986No comparison13SEC filing
Oct 31, 2016Amendment$50,889,675$1,499,995vs Jun 14, 201613SEC filing
Jun 14, 2016Initial$49,389,680No comparison9SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-361834

Source: Form D, filed Mar 3, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Todd Creech Director
Steve Dubin Director
Eric First Executive
Robert Gallotto Executive
James Gamgort Executive
Garheng Kong Director
Tasos Konidaris Executive
Anastasios Konidaris Director, Executive
Stephen Kraus Director
Stephen Krauss Director
Jeremy Lack Director
Alexey Margolin Director
Daniel Orlando Director, Executive
Martin Paz Executive
William Scheinler Executive
Daniel Tasse Director, Executive
James Topper Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
15 Independence Boulevard 4 Th Floor
Warren, NJ, 07059